India's top biotechnology company Biocon Ltd has teamed up with US-based Abraxis BioScience, Inc. to announce the launch of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy.

Read Article